transactivation of the hiv-1 ltr by hsv-1 immediate-early genes.

NLM AIDSLINE Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. Margolis DM; Rabson AB; Straus SE; Ostrove JM; Medical Virology Section,
April 30, 1992

Virology. 1992 Feb;186(2):788-91. Unique Identifier : AIDSLINE Herpes simplex virus type 1 (HSV-1) activates transcription from the long terminal repeat (LTR) promoter region of the human immunodeficiency virus type 1 (HIV-1). HSV-1 immediate-early (IE) genes ICP0 and ICP4 are thought to be important mediators of this process, which is known to involve the induction of the cellular activators NF-kappa B and Sp1. We demonstrate that ICP0 and ICP4 transactivation of the LTR is largely dependent on the presence of NF-kappa B and Sp1 binding sites. However, in Jurkat CD4-positive lymphocytes, HSV-1 activates LTR constructs lacking all NF-kappa B or Sp1 Binding sequences. This effect is still evident when all sequences upstream of the TATA motif are removed. Such enhancer-independent transactivation can be produced by cotransfection of ICP0 and ICP4. Thus HSV-1 IE genes transactivate the HIV-1 LTR both through the induction of NF-kappa B and Sp1 and through another as yet undefined cellular factor. Animal Base Sequence Cell Line Cloning, Molecular DNA, Viral Gene Expression Regulation, Viral Human HIV Long Terminal Repeat/GENETICS Molecular Sequence Data Simplexvirus/GENETICS/PHYSIOLOGY Trans-Activation (Genetics) Viral Proteins/GENETICS Viral Regulatory Proteins/GENETICS Virus Replication/GENETICS JOURNAL ARTICLE

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Photographs from A Day with HIV Now Online Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 ARIZONA: Routine Skin Testing Available Again at Tuberculosis Clinic Starting May 20 NORTH DAKOTA: Officials: 26 Tuberculosis Cases from Grand Forks Outbreak AUSTRALIA: HIV Rates Triple in the Northern Territory in Just 12 Months ARIZONA: Parsons Foundation Gives $3 Million to Southwest Center for HIV/AIDS UNITED STATES: Triple Therapy for Hepatitis C is Effective After Liver Transplantation, but Side-Effects Are Common CANADA: Nunavut Uses Comic Book to Do Sex Education NEW HAMPSHIRE: State Health Officials Urge Hepatitis Testing UNITED STATES: Hepatitis C Testing for People Born Between 1945 and 1965 People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV AUSTRALIA: HIV Rates Triple in the Northern Territory in Just 12 Months ARIZONA: Parsons Foundation Gives $3 Million to Southwest Center for HIV/AIDS People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV No time to lose in the search for an HIV vaccine Health group didn't disclose HIV tests, apologizes NEW JERSEY: Drug Company Donates Thousands to HIV/AIDS Orgs PENNSYLVANIA: Scientists Weaken HIV Infection in Immune Cells Using Synthetic Agents Experimental Gilead drug effective in early-stage leukemia trial Danish researchers issue statement: "We are not on the brink of an HIV cure"
Information in this article was accurate in April 30, 1992. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.